457 related articles for article (PubMed ID: 17068620)
21. Correlation between kisspeptin and biochemical markers in obese and non-obese women with polycystic ovary syndrome.
Gao M; Tao X; Zhang Q; He W; Zhao T; Yuan T
Gynecol Endocrinol; 2023 Dec; 39(1):2215869. PubMed ID: 37236245
[No Abstract] [Full Text] [Related]
22. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
[TBL] [Abstract][Full Text] [Related]
23. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
24. Obesity and serum luteinizing hormone level have an independent and opposite effect on the serum inhibin B level in patients with polycystic ovary syndrome.
Cortet-Rudelli C; Pigny P; Decanter C; Leroy M; Maunoury-Lefebvre C; Thomas-Desrousseaux P; Dewailly D
Fertil Steril; 2002 Feb; 77(2):281-7. PubMed ID: 11821084
[TBL] [Abstract][Full Text] [Related]
25. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.
Glintborg D; Andersen M; Richelsen B; Bruun JM
Clin Endocrinol (Oxf); 2009 Nov; 71(5):652-8. PubMed ID: 19170716
[TBL] [Abstract][Full Text] [Related]
26. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
[TBL] [Abstract][Full Text] [Related]
27. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Androgen Levels, Endocrine and Metabolic Indices, and Clinical Findings in Women with Polycystic Ovary Syndrome in Uygur and Han Ethnic Groups from Xinjiang Province in China.
Zhao H; Song X; Zhang L; Xu Y; Wang X
Med Sci Monit; 2018 Sep; 24():6774-6780. PubMed ID: 30252834
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome].
Roa Barrios M; Arata-Bellabarba G; Valeri L; Velázquez-Maldonado E
Endocrinol Nutr; 2009 Feb; 56(2):59-65. PubMed ID: 19627713
[TBL] [Abstract][Full Text] [Related]
30. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
31. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.
Eldar-Geva T; Spitz IM; Groome NP; Margalioth EJ; Homburg R
Hum Reprod; 2001 Dec; 16(12):2552-6. PubMed ID: 11726573
[TBL] [Abstract][Full Text] [Related]
32. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women.
Maitra A; Pingle RR; Menon PS; Naik V; Gokral JS; Meherji PK
Int J Fertil Womens Med; 2001; 46(5):271-7. PubMed ID: 11720200
[TBL] [Abstract][Full Text] [Related]
33. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
34. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Demirel F; Bideci A; Cinaz P; Camurdan MO; Biberoğlu G; Yesilkaya E; Hasanoğlu A
Clin Endocrinol (Oxf); 2007 Jul; 67(1):129-34. PubMed ID: 17465999
[TBL] [Abstract][Full Text] [Related]
35. Examination of angiopoietin-like protein 4, neuropeptide Y, omentin-1 levels of obese and non-obese patients with polycystic ovary syndrome.
Güneş M; Bukan N
Gynecol Endocrinol; 2015; 31(11):903-6. PubMed ID: 26291814
[TBL] [Abstract][Full Text] [Related]
36. Macrophage migration inhibitory factor in obese and non obese women with polycystic ovary syndrome.
Mejia-Montilla J; Álvarez-Mon M; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Suarez-Torres I; Bravo-Henríquez A
Endocrinol Nutr; 2015 Jan; 62(1):31-7. PubMed ID: 25458401
[TBL] [Abstract][Full Text] [Related]
37. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
38. [Effect of abdominal acupuncture therapy on the endocrine and metabolism in obesity-type polycystic ovarian syndrome patients].
Lai MH; Ma HX; Yao H; Liu H; Song XH; Huang WY; Wu XK
Zhen Ci Yan Jiu; 2010 Aug; 35(4):298-302. PubMed ID: 21090334
[TBL] [Abstract][Full Text] [Related]
39. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
[TBL] [Abstract][Full Text] [Related]
40. Color Doppler analysis in lean and obese women with polycystic ovary syndrome.
Battaglia C; Artini PG; Genazzani AD; Sgherzi MR; Salvatori M; Giulini S; Volpe A
Ultrasound Obstet Gynecol; 1996 May; 7(5):342-6. PubMed ID: 8774099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
